TNFRSF11B Antibody

What is TNFRSF11B and what are its primary functions in human physiology?

TNFRSF11B, also known as Osteoprotegerin (OPG) or osteoclastogenesis inhibitory factor (OCIF), belongs to the tumor necrosis factor (TNF) receptor superfamily. It functions primarily as a decoy receptor for TNFSF11 (RANKL), inhibiting osteoclastic activity and promoting bone formation by preventing RANKL from binding to its receptor TNFRSF11A (RANK) . Beyond bone metabolism, TNFRSF11B plays significant roles in:

• Immune regulation, particularly in suppressing memory CD4+ T cell activation in cancer microenvironments

• Vascular endothelial function, with elevated levels associated with endothelial dysfunction in sepsis-ARDS

• Inflammatory response modulation, as evidenced by its involvement in rheumatoid arthritis pathophysiology

The protein consists of 401 amino acids with a calculated molecular weight of 46 kDa, though it's typically observed at approximately 56 kDa in Western blot applications due to post-translational modifications .

What are the different types of TNFRSF11B antibodies available for research, and how do they differ?

Researchers can utilize several types of TNFRSF11B antibodies, each with specific characteristics:

The monoclonal antibody (clone 69146) demonstrates specific neutralizing activity against recombinant human Osteoprotegerin/TNFRSF11B in functional assays, with an ND50 (neutralizing dose) typically between 0.15-0.3 μg/mL . In contrast, polyclonal antibodies offer broader epitope recognition, making them versatile for detection applications across multiple techniques .

How does TNFRSF11B expression vary across different tissues and disease states?

TNFRSF11B expression exhibits significant tissue-specific and disease-state variation:

• Normal tissues: Detected in human milk and expressed in kidney tissue

• Cancer contexts: Increased expression observed in colorectal cancer, correlating with poorer prognosis and suppression of memory CD4+ T cell infiltration

• Inflammatory conditions:

  • In rheumatoid arthritis (RA), TNFRSF11B expression remains relatively constant even when RANKL and RANK expression decrease following methotrexate treatment

  • In sepsis-ARDS, plasma TNFRSF11B levels are significantly elevated compared to healthy controls, with concentrations reaching 10-20 ng/mL

Interestingly, while TNFRSF11B functions primarily as a bone metabolism regulator, its immunomodulatory effects appear to be context-dependent, sometimes promoting immunosuppression as observed in colon cancer microenvironments .

What are the optimal conditions for using TNFRSF11B antibodies in Western blot applications?

For optimal Western blot detection of TNFRSF11B, researchers should consider the following protocol parameters:

When analyzing TNFRSF11B expression changes, as in methotrexate treatment studies, Western blot can effectively demonstrate differences in both cellular and soluble TNFRSF11B levels. In rheumatoid arthritis fibroblasts, methotrexate treatment showed no significant changes in OPG protein expression while decreasing RANKL levels , highlighting the importance of analyzing related proteins within the same pathway.

How should TNFRSF11B antibodies be used for immunohistochemistry of tissue samples?

For effective immunohistochemical detection of TNFRSF11B in tissue samples:

Semi-quantitative double-blind microscopic analysis can be employed to evaluate expression levels, as demonstrated in studies examining TNFRSF11B expression in rheumatoid arthritis synovial biopsies before and after methotrexate treatment . This approach allows for objective assessment of expression changes in response to therapeutic interventions.

What neutralization assays can be performed to evaluate TNFRSF11B antibody functionality?

Functional neutralization assays provide critical information about TNFRSF11B antibody activity:

The established neutralization assay involves:

• Preparation of L-929 mouse fibroblast cells treated with actinomycin D (0.5 μg/mL)

• Addition of Recombinant Human TRAIL/TNFSF10 (50 ng/mL) to induce cytotoxicity

• Addition of Recombinant Human Osteoprotegerin/TNFRSF11B Fc Chimera (0.1 μg/mL) to inhibit TRAIL-induced cytotoxicity

• Titration of anti-TNFRSF11B monoclonal antibody to neutralize OPG's inhibitory effect on TRAIL

• Measurement of cell viability to determine neutralizing activity

The neutralizing dose (ND50) typically ranges from 0.15-0.3 μg/mL when using the Mouse Anti-Human Osteoprotegerin/TNFRSF11B Monoclonal Antibody (Clone 69146) . This assay specifically evaluates the antibody's ability to block OPG's decoy receptor function, which is essential for validating antibody functionality in research applications.

How is TNFRSF11B implicated in sepsis-ARDS pathophysiology and what are the appropriate experimental designs to study this?

TNFRSF11B has emerged as a potential biomarker for sepsis-associated acute respiratory distress syndrome (ARDS). Recent research revealed:

• Elevated plasma TNFRSF11B levels in sepsis-ARDS patients:

  • Significant increase compared to healthy controls

  • Peak plasma concentrations of 10-20 ng/mL observed

• Association with vascular endothelial dysfunction:

  • Experimental validation in three models:

    • Patient plasma samples

    • LPS-induced mouse models

    • LPS-stimulated HUVECs

For studying TNFRSF11B in sepsis-ARDS, researchers should consider:

• In vitro experiments: Use 10 ng/mL TNFRSF11B to stimulate HUVECs and measure endothelial junction proteins

• Protein assessment: Evaluate changes in syndecan-1, claudin-5, VE-cadherin, occludin, aquaporin-1, caveolin-1 (all decreased), and connexin-43 (increased) after TNFRSF11B stimulation

• Functional assays: Measure endothelial permeability using transwell assays with fluorescent tracers

These investigations suggest TNFRSF11B could serve as both a predictive and diagnostic biomarker for vascular endothelial damage in sepsis-ARDS contexts .

What is the role of TNFRSF11B in cancer immunology, particularly in colorectal cancer?

TNFRSF11B plays a significant immunosuppressive role in colorectal cancer:

• Prognostic significance:

  • Identified as an independent risk factor for colon cancer prognosis

  • Closely associated with tumor stage and lymph node metastasis

• Immunosuppressive mechanisms:

  • Suppresses memory CD4+ T cell infiltration in the tumor microenvironment

  • Acts as a competitive inhibitor of the TNFSF11-TNFRSF11A pathway

  • Remodels the immune barrier of the colonic mucosa

• Experimental validation methods:

  • Bioinformatic analysis: TCGA-COAD dataset (n=514) and single-cell RNA sequencing (290 colorectal cancer cells)

  • Immunohistochemistry: Validated in 86 patient samples

  • Flow cytometry: Demonstrated decreased infiltration of central memory CD4+ T cells and effector memory CD4+ T cells in colorectal cancer microenvironment (p<0.001)

Researchers investigating TNFRSF11B in cancer contexts should employ a multi-omics approach combining transcriptomics, proteomics, and functional assays to comprehensively characterize its immunomodulatory effects.

How does TNFRSF11B expression change in rheumatoid arthritis and following methotrexate treatment?

TNFRSF11B expression in rheumatoid arthritis (RA) shows distinct patterns compared to related molecules in the RANK/RANKL pathway:

• Expression pattern in untreated early RA:

  • Detectable OPG expression in synovial tissue

  • Part of the RANK/RANKL/OPG axis dysregulation in RA pathophysiology

• Response to methotrexate treatment:

  • RANKL: Significant decrease in mRNA levels and protein expression (both cellular and soluble)

  • OPG: No significant changes in mRNA or protein levels following methotrexate treatment

  • This differential response alters the RANKL/OPG ratio, potentially impacting osteoclastogenesis

• Detection methods:

  • mRNA analysis: qRT-PCR for transcriptional changes

  • Protein detection: Western blot for cellular expression, ELISA for soluble factors

  • Tissue assessment: Immunohistochemistry of synovial biopsies with semi-quantitative double-blind microscopic analysis

These findings suggest that while methotrexate effectively reduces RANKL expression in RA, OPG levels remain relatively stable, potentially representing a homeostatic mechanism in bone metabolism regulation.

What are common technical challenges when working with TNFRSF11B antibodies and how can they be addressed?

Researchers may encounter several technical challenges when working with TNFRSF11B antibodies:

Additionally, researchers should consider that soluble TNFRSF11B may be present in biological fluids at varying concentrations (10-20 ng/mL in sepsis-ARDS patients) , potentially interfering with assays if not accounted for in experimental design.

How should researchers optimize TNFRSF11B antibody dilutions for different applications?

Optimal antibody dilutions vary by application technique and specific antibody used:

Each new lot of antibody and sample type may require re-optimization. Researchers should document optimization experiments thoroughly, including positive and negative controls, to ensure reproducibility across experiments.

What sample preparation considerations are important for accurate TNFRSF11B detection?

Proper sample preparation is critical for successful TNFRSF11B detection:

• Protein extraction and preservation:

  • Include protease inhibitors in lysis buffers to prevent degradation

  • For tissue samples, rapid processing and flash-freezing help maintain protein integrity

  • Store samples at -20°C in PBS with 0.02% sodium azide and 50% glycerol (pH 7.3) for long-term stability

• Specific preparation by application:

  • Western blot: Complete protein denaturation essential; consider non-reducing conditions if antibody recognizes conformational epitopes

  • IHC: Antigen retrieval critical—use TE buffer pH 9.0 or alternatively citrate buffer pH 6.0

  • Flow cytometry: When studying T cell subpopulations, use fresh samples and appropriate surface markers (e.g., CD45RO, CCR7) to distinguish central memory from effector memory CD4+ T cells

• Sample source considerations:

  • Human milk has been validated for Western blot detection

  • HepG2 cells work well for immunofluorescence

  • When measuring plasma TNFRSF11B in sepsis-ARDS patients, be aware that concentrations may reach 10-20 ng/mL

What are the current hypotheses regarding TNFRSF11B's dual roles in bone metabolism and immune regulation?

TNFRSF11B functions extend beyond its canonical role in bone metabolism, with emerging evidence supporting its significant immunoregulatory functions:

• Mechanistic intersection points:

  • TNFRSF11B acts as a decoy receptor for TNFSF11 (RANKL), competitively inhibiting TNFSF11-TNFRSF11A pathway activation

  • This pathway functions in both osteoclastogenesis and immune cell development/function

  • The TNFSF11/TNFRSF11A axis is critical for lymph node development, as knockout mice show impeded formation of secondary lymph nodes and Peyer's patches

• Context-dependent immune effects:

  • Inflammatory balance: In rheumatoid arthritis, OPG levels remain stable despite methotrexate-induced RANKL reduction, potentially maintaining a protective effect against bone erosion

  • Colon cancer immunosuppression: TNFRSF11B remodels the colon mucosal immune barrier, alleviating local inflammation but potentially promoting tumor evasion

  • Sepsis-related vascular dysfunction: Elevated TNFRSF11B correlates with endothelial junction protein alterations that could affect immune cell trafficking

Future research should investigate the molecular switches that determine TNFRSF11B's function in different microenvironments and how these might be therapeutically manipulated.

How might TNFRSF11B serve as a biomarker or therapeutic target in inflammatory and neoplastic diseases?

TNFRSF11B shows significant potential as both a biomarker and therapeutic target:

• Biomarker applications:

  • Sepsis-ARDS: Elevated plasma TNFRSF11B (10-20 ng/mL) correlates with vascular endothelial dysfunction, suggesting utility as a diagnostic and predictive biomarker

  • Colorectal cancer: High TNFRSF11B expression correlates with poorer prognosis, especially in TNM stage III disease, and decreased memory CD4+ T cell infiltration

  • Combined biomarker panels: TNFRSF11B could complement other inflammation markers for improved diagnostic precision

• Therapeutic targeting strategies:

  • Neutralizing antibodies: Similar to the experimental antibody (clone 69146) that blocks TNFRSF11B activity in vitro

  • Pathway modulation: Targeting the TNFSF11/TNFRSF11A/TNFRSF11B axis to restore immune function in cancer microenvironments

  • Context-specific approaches: Inhibiting TNFRSF11B might benefit cancer immunotherapy by enhancing T cell infiltration, while augmenting it could help in inflammatory conditions

• Translational challenges:

  • TNFRSF11B's dual roles in bone metabolism and immunity necessitate careful consideration of potential off-target effects

  • Patient stratification based on TNFRSF11B expression patterns may be necessary for effective targeting

Research exploring these applications should include appropriate control groups and comprehensive safety assessments given TNFRSF11B's diverse physiological roles.

What emerging experimental techniques might advance our understanding of TNFRSF11B biology?

Several cutting-edge techniques could significantly advance TNFRSF11B research:

• Single-cell analysis approaches:

  • Single-cell RNA sequencing to map TNFRSF11B expression across different cell types and disease states

  • Mass cytometry (CyTOF) to simultaneously detect TNFRSF11B alongside multiple immune markers

  • These techniques would help identify previously unknown cell populations expressing or responding to TNFRSF11B

• Advanced imaging methods:

  • Multiplex immunofluorescence to visualize TNFRSF11B in spatial context with other proteins

  • Intravital microscopy to observe TNFRSF11B-mediated interactions in living tissues

  • These approaches would provide insight into the spatial organization of TNFRSF11B-expressing cells within tissue microenvironments

• Functional genomics:

  • CRISPR-Cas9 screening to identify genes that interact with TNFRSF11B signaling

  • Conditional knockout models to assess tissue-specific functions of TNFRSF11B

  • These tools would help delineate the complex regulatory networks governing TNFRSF11B expression and function

• Protein interaction studies:

  • Proximity labeling techniques to identify novel TNFRSF11B binding partners

  • Structural biology approaches to understand the molecular basis of TNFRSF11B interactions

  • These methods would expand our understanding of TNFRSF11B beyond its canonical RANKL-binding activity

Implementing these advanced techniques would provide multi-dimensional insights into TNFRSF11B biology and potentially reveal novel therapeutic opportunities.